Ovarian cancer: Current status and strategies for improving therapeutic outcomes
Tóm tắt
Of all the gynecologic tumors, ovarian cancer (OC) is known to be the deadliest. Advanced‐stages of OC are linked with high morbidity and low survival rates despite the immense amount of research in the field. Shortage of promising screening tools for early‐stage detection is one of the major challenges linked with the poor survival rate for patients with OC. In OC, therapeutic management is used with multidisciplinary approaches that includes debulking surgery, chemotherapy, and (rarely) radiotherapy. Recently, there is an increasing interest in using immunomodulation for treating OC. Relapse rates are high in this malignancy and averages around every 2‐years. Further treatments after the relapse are more intense, increasing the toxicity, resistance to chemotherapy drugs, and financial burden to patients with poor quality‐of‐life. A procedure that has been studied to help reduce the morbidity rate involves pre‐sensitizing cancer cells with standard therapy in order to produce optimal results with minimum dosage. Utilizing such an approach, platinum‐based agents are effective due to their increased response to platinum‐based chemotherapy in relapsed cases. These chemo‐drugs also help address the issue of drug resistance. After conducting an extensive search with available literature and the resources for clinical trials, information is precisely documented on current research, biomarkers, options for treatment and clinical trials. Several schemes for enhancing the therapeutic responses for OC are discussed systematically in this review with an attempt in summarizing the recent developments in this exciting field of translational/clinical research.
Từ khóa
Tài liệu tham khảo
Shah CA, 2009, Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125, Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive, Oncology, 18, 1365
Jaaback K, 2016, Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer, Cochrane Database Syst Rev
Eliopoulos AG, 1995, The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl‐2, Oncogene, 11, 1217
Johnson SW, 1997, Increased platinum‐DNA damage tolerance is associated with cisplatin resistance and cross‐resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines, Can Res, 57, 850
Stavrovskaya AA, 2000, Cellular mechanisms of multidrug resistance of tumor cells, Biochemistry, 65, 95
Maliepaard M, 1999, Overexpression of the BCRP/MXR/ABCP gene in a topotecan‐selected ovarian tumor cell line, Can Res, 59, 4559
Kajiyama H, 2007, Chemoresistance to paclitaxel induces epithelial‐mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells, Int J Oncol, 31, 277
Wiggans AJ, 2015, Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer, Cochrane Database Syst Rev, 5
Yellepeddi VK, 2012, Comparative evaluation of small‐molecule chemosensitizers in reversal of cisplatin resistance in ovarian cancer cells, Anticancer Res, 32, 3651
Diab Y, 2017, Targeted therapy in ovarian cancer. A comprehensive systematic review of literature, Anticancer Res, 37, 2809